Combination treatment for leukemia with genetic change
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests two drugs (blinatumomab and revumenib) given together for people with a type of acute lymphoblastic leukemia (ALL) that has a specific genetic change called KMT2A. The combination aims to kill leukemia cells and may be an option for people whose leukemia has returned or not improved, or for older or less fit adults newly diagnosed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older.
- Diagnosed with B-cell ALL that has the KMT2A gene change.
- Leukemia is relapsed or refractory, or has measurable residual disease, or you are newly diagnosed and older than 60 or unable to tolerate intensive chemo.
- Adequate liver, kidney, pancreas, and heart function.
- Willing to use effective birth control during the study and for a period after.
- No active serious infections or untreated central nervous system leukemia.
- No major heart issues in the past 6 months.
- No active hepatitis B or C, and if you have HIV, your viral load must be undetectable.
- No prior stem cell transplant in the last 60 days, or immunotherapy in the last 60 days.
- Weigh at least 40 kg (about 88 pounds).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs—blinatumomab (an immune therapy) and olverembatinib (a targeted pill)—for people with a specific type of ALL that has the Ph chromosome or BCR::ABL1 gene. It aims to see if this combination works well in controlling the disease.
This trial tests a combination of targeted and chemotherapy medicines as first treatment for newly diagnosed B-cell acute lymphoblastic leukemia (ALL) or related lymphoblastic lymphoma. It aims to improve how well treatment controls the leukemia and how long people can stay in remission.
This study tests a combination of two medicines, blinatumomab and revumenib, for people with a specific genetic form of leukemia (KMT2A). The goal is to see if adding revumenib helps the treatment work better and keeps the cancer in remission.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This trial tests a combination of two treatments—blinatumomab and a special type of immune cell called iNKT—to fight B-cell acute lymphoblastic leukemia (ALL) that has returned or is not responding well after prior treatment. The goal is to see if this combination is safe and effective for patients who have had a relapse or new minimal residual disease (MRD) after previous treatment.
This study tests a treatment plan for babies under 1 year with leukemia that has a KMT2A gene rearrangement. It may help by trying to improve outcomes in this high-risk group, sometimes using a drug called blinatumomab (depending on eligibility).
Hear when a new Blinatumomab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.